2026 Catalysts: Breakthrough progress in renal disease

Renal disease has secured its position as an area of rising pharma and investor interest, thanks in part to the validation of surrogate endpoints for IgA nephropathy and the streamlined development and regulatory path that resulted. This year, late-stage clinical and regulatory progress in IgA nephropathy should continue to advance, while driving progress in other rare kidney diseases. 

The next year is set to deliver Phase III data for at least two new IgA nephropathy therapies, an initial regulatory submissions for a third, and a possible label expansion to include IgAN for another...